Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions – A cross-sectional study in six EU member states-Reference-Cited by-同舟云学术

Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions – A cross-sectional study in six EU member states

Published:2024-01 Issue:3 Volume:42 Page:556-563
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Buhl Caroline^ORCID,Jacobsen Ramune^ORCID,Almarsdóttir Anna Birna,Abtahi Shahab^ORCID,Andersen Armin^ORCID,Deligianni Elena,Dermiki-Gkana Foteini,Kontogiorgis Christos,Oikonomou Chara^ORCID,Kursite Mirdza,Poplavska Elita,Hegger Ingrid,van der Goot Marloes,Sousa Ferreira Paula Barão,Ribeiro-Vaz Inês,Silva Ana Marta,Kos Mitja,Lipovec Nanča Čebron,van Vliet Ella,Alves Teresa Leonardo

Funder

European Medicines Agency

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference31 articles.

1. Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination;Buoninfante;npj Vaccines,2022

2. COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): a systematic review and post hoc analysis;Hafeez;Clin Appl Thromb Hemost,2021

3. EMA. EMA raises awareness of clinical care recommendations to manage suspected thrombosis with thrombocytopenia syndrome. Amsterdam: European Medicines Agency; 2021 [accessed 2023 Jul 14]. Available from: https://www.ema.europa.eu/en/news/ema-raises-awareness-clinical-care-recommendations-manage-suspected-thrombosis-thrombocytopenia.

4. EMA. Vaxzevria - Procedural steps taken and scientific information after the authorisation. Amsterdam: European Medicines Agency; 2021 [accessed 2023 Jul 14]. Available from: https://www.ema.europa.eu/en/documents/procedural-steps-after/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-procedural-steps-taken-scientific-information_en.pdf.

5. EMA. DHPC - COVID-19 Vaccine AstraZeneca: Risk of thrombocytopenia and coagulation disorders. Amsterdam: European Medicines Agency; 2021 [accessed 2023 Jul 14]. Available from: https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-vaxzevria-previously-covid-19-vaccine-astrazeneca_en.pdf.